Filed Pursuant to Rule 424(b)(3)
Registration No. 333-267419
PROSPECTUS
Li-Cycle Holdings Corp.
Secondary Offering of
96,579,362 Common Shares
This prospectus relates to the offer and sale from time to time by the selling shareholders named in this prospectus or their permitted transferees (collectively, the “selling shareholders”) of up to 96,579,362 common shares, without par value (the “common shares”) of Li-Cycle Holdings Corp., an Ontario corporation (“we” or the “Company”). This prospectus covers any additional securities that may become issuable by reason of share splits, share dividends, and other events described herein.
The common shares covered by this prospectus that may be offered and sold by the selling shareholders include (i) 59,113,532 common shares issued to certain former shareholders and optionholders of Li-Cycle Corp., an Ontario corporation, at the closing of the business combination by and among the Company, Li-Cycle Corp., and Peridot Acquisition Corp., an Ontario corporation (“Peridot”), on August 10, 2021, as a result of which the Company became a new public company (the “Business Combination”), (ii) 7,500,000 common shares issued to Peridot Class B Holders (as defined herein) in connection with the Business Combination, (iii) 1,586,720 common shares issued following the exercise of private placement warrants (the “private placement warrants”) held by Peridot Acquisition Sponsor, LLC, a Delaware limited liability company (the “Sponsor”), (iv) 12,056,835 common shares issued to certain institutions and accredited investors in the PIPE Financing (as defined herein), (v) 11,021,923 common shares issuable upon conversion of outstanding unsecured convertible notes held by a selling shareholder (the “2021 Convertible Notes”) or pursuant to any other term of the 2021 Convertible Notes, including as a result of any of the payment-in-kind (“PIK”) provisions of the 2021 Convertible Notes, and (vi) 5,300,352 common shares issued pursuant to the LG Subscription (as defined herein).
We are registering the offer and sale of the common shares covered by this prospectus to satisfy certain registration rights we have granted to the selling shareholders. The selling shareholders may offer all or part of the common shares covered by this prospectus for resale from time to time through public or private transactions, at either prevailing market prices or at privately negotiated prices. These common shares are being registered to permit the selling shareholders to sell common shares from time to time, in amounts, at prices and on terms determined at the time of offering. The selling shareholders may sell these common shares through an underwritten offering, ordinary brokerage transactions, directly to market makers of our common shares or through any other means described in the section entitled “Plan of Distribution” herein. In connection with any sales of common shares offered hereunder, the selling shareholders and any underwriters, agents, brokers or dealers participating in such sales may be deemed to be “underwriters” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). If our common shares are sold through underwriters or broker-dealers, the selling shareholders will be responsible for underwriting discounts or commissions or agent’s commissions.
All of the common shares offered by the selling shareholders pursuant to this prospectus will be sold by the selling shareholders for their respective accounts. We will not receive any of the proceeds from these sales.
We will pay certain expenses associated with the registration of the common shares covered by this prospectus, as described in the section entitled “Plan of Distribution.”
Our common shares are currently listed on The New York Stock Exchange under the symbol “LICY”. On September 13, 2022, the last reported sale price of our common shares as reported on The New York Stock Exchange was $7.11 per common share.
We may amend or supplement this prospectus from time to time by filing amendments or supplements. You should read this entire prospectus and any amendments or supplements carefully before you make your investment decision.
We are currently an “emerging growth company” as that term is defined in the Jumpstart Our Business Startups Act of 2012 and, as such, are subject to reduced public company reporting requirements. We are also a “foreign private issuer” and will report under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies.
Our principal executive offices are located at 207 Queen’s Quay West, Suite 590, Toronto, Ontario , M5J 1A7, Canada.
Investing in our common shares involves a high degree of risk. Before buying any common shares, you should carefully read the discussion of material risks of investing in our common shares in the section entitled “Risk Factors” beginning on page 10 of this prospectus and the other information included or incorporated by reference in the prospectus and the applicable prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these common shares or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Prospectus dated September 26, 2022